| CANCER-RESEARCH-UK |
CANCER-RESEARCH-UK |
90%
|
Lineage and CRT effectuated the option by simultaneously entering into a license agreement (the “CRT License Agreement”). |
| HADASIT |
HADASIT |
85%
|
The Hadasit License Agreement was amended on December 17, 2021 by a letter agreement pursuant to which CCN is obligated to pay a maximum of 21.5% of any milestone payments Lineage receives under the … |
| IMMUNOMIC-THERAPEUTICS-INC |
IMMUNOMIC-THERAPEUTICS-INC |
85%
|
Lineage notified Immunomic Therapeutics, Inc. (“ITI”) of the termination of the collaboration agreement that Lineage had entered into with ITI in April 2021 (the “ITI Agreement”) |
| ROCHE-AGREEMENT |
ROCHE-AGREEMENT |
85%
|
The Hadasit License Agreement was amended on December 17, 2021 by a letter agreement pursuant to which CCN is obligated to pay a maximum of 21.5% of any milestone payments Lineage receives under the … |
| APLS |
Apellis Pharmaceuticals, Inc. |
72%
|
or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, i… |
| APLS |
Apellis Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from APLS graph: Reciprocal relationship from LCTX graph: or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts a… |
| IMDX |
Insight Molecular Diagnostics Inc. |
72%
|
Reciprocal relationship from IMDX graph: ission or proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete … |
| NVO |
Novo Nordisk A/S |
72%
|
Reciprocal relationship from NVO graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from NVO graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from NVO grap… |
| NVO |
Novo Nordisk A/S |
72%
|
or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, i… |
| ABBV |
AbbVie Inc. |
62%
|
Reciprocal relationship from ABBV graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from ABBV g… |
| ABBVIE-CENTURY-THERAPEUTICS-BAYER-AG |
ABBVIE-CENTURY-THERAPEUTICS-BAYER-AG |
62%
|
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Major Sources of Revenues The following table shows our major sources of revenue… |
| APELLIS-PHARMACEUTICALS-INC |
APELLIS-PHARMACEUTICALS-INC |
62%
|
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Major Sources of Revenues The following table shows our major sources of revenue… |
| ASTERIAS-BIOTHERAPEUTICS-INC |
ASTERIAS-BIOTHERAPEUTICS-INC |
62%
|
ion price allocated to remaining performance obligations as of December 31, 2025 was $ 18.4 million, of which $ 15.7 million is reported as deferred revenues. The $ 18.4 million is estimated to be su… |
| ASTERIAS-BIOTHERAPEUTICS-INCORPORATED |
ASTERIAS-BIOTHERAPEUTICS-INCORPORATED |
62%
|
d as part of the programs under which the grants were given, continue to apply even after the repayment of royalties in full by the grant recipient. Part of CCN’s research and development efforts hav… |
| ASTI |
Ascent Solar Technologies, Inc |
62%
|
Reciprocal relationship from ASTI graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from ASTI graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from ASTI g… |
| BIO-HOLDINGS-LTD |
BIO-HOLDINGS-LTD |
62%
|
asit Bio-Holdings Ltd (“HBL”) and for the shares held in OncoCyte Corporation (“OCX”) as marketable equity securities in accordance with ASC 320-10-25, Investments – Debt and Equity Securities , as a… |
| HADASIT-BIO-HOLDINGS-LTD |
HADASIT-BIO-HOLDINGS-LTD |
62%
|
E CELL THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (CONTINUED) (UNAUDITED) For contracts with customers, including collaboration partners whic… |
| INC-ASTELLAS-PHARMA-INC |
INC-ASTELLAS-PHARMA-INC |
62%
|
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Major Sources of Revenues The following table shows our major sources of revenue… |
| ONCOCYTE-CORPORATION |
ONCOCYTE-CORPORATION |
62%
|
asit Bio-Holdings Ltd (“HBL”) and for the shares held in OncoCyte Corporation (“OCX”) as marketable equity securities in accordance with ASC 320-10-25, Investments – Debt and Equity Securities , as a… |
| REGENERON-PHARMACEUTICALS-SANTEN-PHARMACEUTICALS |
REGENERON-PHARMACEUTICALS-SANTEN-PHARMACEUTICALS |
62%
|
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Major Sources of Revenues The following table shows our major sources of revenue… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
62%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from REGN g… |
